FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Catimated average I	hurdon								

0.5

hours per response:

Check this box if no	longer subject to
Section 16. Form 4	or Form 5
obligations may cor	ntinue. See
Instruction 1(h)	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					UI V	Section	1 30(11)	OI LITE	IIIVESIII	ient C	Ullipally Act	01 1940							
1. Name and Address of Reporting Person* MACKAY MARTIN					AI	2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC ALXN								5. Relationship of Reporting Person(s) to Iss (Check all applicable) Director 10% Ow				Owner	
, , , , , , , , , , , , , , , , , , ,														X	Offic belov	er (give title w)	Other below	(specify y)	
(Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS, INC 352 KNOTTER DRIVE					05/	3. Date of Earliest Transaction (Month/Day/Year) 05/14/2014									EVP & Global Head of R&D				
					_ 4. If	Amen	dment,	, Date	of Origi	nal File	ed (Month/Da	ay/Year)		3. Indiv ₋ine)	idual o	r Joint/Group	Filing (Check A	Applicable	
(Street) CHESHI	RE CI	Γ (06410											X	Forn	n filed by One	Reporting Per	son	
					-										Form filed by More than One Reporting Person				
(City)	(St	ate) (Zip)																
		Tabl	e I - N	on-Deriv	ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or E	Benefici	ially	Owne	∍d			
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/N					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar					nd 5) Secui Bene		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price		Trans	action(s) 3 and 4)		(Instr. 4)	
Common Stock, par value \$.0001 per share 05/14/20					2014	14		S		3,574(1)	D	\$160.	85(2)	24,426		D			
		Та	ble II								osed of, convertib			•	vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)			Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e Exerc ation Da h/Day/\		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			r. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$160.25 \$161.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Remarks:

/s/ Michael Greco, Attorney-in-Fact 05/15/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.